• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer

byDavid ArsaniousandShaidah Deghan, MSc. MD
December 2, 2016
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Among patients with platinum-sensitive recurrent ovarian cancer, those who received the PARP inhibitor niraparib demonstrated significantly increased progression-free survival compared to patients who received placebo.

2. The most common treatment-emergent hematologic events reported included thrombocytopenia, anemia, and neutropenia.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Selective inhibitors of poly(adenosine diphosphate [ADP]-ribose) polymerases (PARP), a family of nuclear proteins that are involved in DNA damage detection and repair, are an emerging class of antineoplastic drugs that have received significant attention in recent years for their success in the treatment of several cancers. This randomized trial involving patients with platinum-sensitive, recurrent ovarian cancer enrolled two independent cohorts on the basis of the presence or absence of gBRCA which is a germline of the BRCA mutation. Within each cohort, patients were randomly assigned in a 2:1 ratio to receive niraparib or placebo.

The study’s primary end point, progression-free survival (PFS), was defined as the time from randomization to earliest date of progression or death from any cause. This was assessed by serial pelvic CT or MRI scans. The primary endpoint was significantly lengthened in the niraparib group regardless of their gBRCA status. In both groups, the most common treatment emergent hematologic events reported were thrombocytopenia, anemia, and neutropenia.

This study draws strength from its strict inclusion criteria of patients with tumors bearing high-grade serous histologic features and who also experienced disease progression at >6 months after a demonstrated response to platinum-based chemotherapy, in addition to its standardized protocol for radiographic assessment of progression. Nonetheless, one limitation of the study was its relatively short median follow-up duration of 16.9 months.

Click to read the study, published in NEJM

RELATED REPORTS

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

Pembrolizumab improves survival outcomes in cervical cancer patients

Relevant Reading: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

In-Depth [randomized controlled trial]: This randomized, placebo-controlled, phase 3 trial assessed a primary end point of progression-free survival in patients with platinum-sensitive, recurrent ovarian cancer in a germline BRCA-mutant (gBRCA) and a non-germline BRCA-mutant cohort. Among the gBRCA cohort, median PFS was 21.0 months for the niraparib group compared to 5.5 months for the placebo group (HR 0.27; 95%CI 0.17 to 0.41; p < 0.001). A trend of increased survival was also observed in the non-gBRCA cohort. The non-gBRCA group showed 9.3 months of PFS in the niraparib group compared to 3.9 months in the placebo group (HR 0.45; 95%CI 0.34 to 0.61; p < 0.001). The most common treatment emergent hematologic events were thrombocytopenia (61.3% in the niraparib group vs. 5.6% in the placebo group), anemia (50.1% vs. 6.7%), and neutropenia (30.2% vs. 6.1%).

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ovarian cancerplatinum-based chemotherapy
Previous Post

Dapivirine-containing vaginal ring linked to reduced HIV-1 transmission

Next Post

Families and providers caring for medically complex patients share goals

RelatedReports

Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

March 21, 2022
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Chronic Disease

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

February 15, 2022
Cervical cancer screening practices less cost-effective than suggested guidelines
Obstetrics

Pembrolizumab improves survival outcomes in cervical cancer patients

February 15, 2022
#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality
StudyGraphics

#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality

July 18, 2021
Next Post
American Academy of Pediatrics recommends standards for adverse event disclosures

Families and providers caring for medically complex patients share goals

Smoking during pregnancy associated with aerobic fitness of children

Low-intensity smoking associated with increased mortality

AAP addresses neonatal pain prevention

Noninvasive respiratory support, methylxanthines among interventions that reduce re-intubations in preterm infants

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.